STOCK TITAN

UPS Announces Agreement to Acquire Smartways Logistics

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Planned acquisition enhances how UPS serves time-critical complex healthcare needs across Asia Pacific region

ATLANTA--(BUSINESS WIRE)-- UPS (NYSE: UPS) today announced it has entered into an agreement to acquire Smartways Logistics (Smartways), a healthcare logistics provider serving Australia and New Zealand. Once completed, the acquisition will enhance UPS Healthcare’s time-critical transportation capabilities in the region.

Smartways enables healthcare customers to move critical shipments quickly and reliably, with specialized services for life sciences, medical devices, clinical trials and radiopharmaceuticals. The acquisition will build on UPS Healthcare’s ability to deliver for customers with urgent and complex logistics needs, while expanding the services available in Australia, New Zealand and the Asia Pacific region.

“As healthcare becomes increasingly complex, logistics plays an even more critical role. It takes specialized capabilities and precision at every step to help vital healthcare products reach patients safely, reliably and when they’re needed,” said Wilfredo Ramos, UPS EVP and Chief International, Healthcare and Supply Chain Solutions Officer. “Together with Smartways, we can better serve UPS Healthcare customers and the patients who depend on them.”

“Smartways has grown into a successful healthcare logistics provider in Australia and New Zealand, built on the dedication of our people and medical couriers,” said Marcus Wyborn, Smartways Chair. “The proposed acquisition represents an exciting next chapter, bringing together our expertise in complex, time-critical healthcare logistics with UPS’s global network to optimize end-to-end logistics solutions for our clients. I’d also like to recognize The Riverside Company for its partnership and support. We’re proud of what we’ve achieved together and confident about the opportunities ahead.”

The planned acquisition is part of a broader UPS strategy to continue investing in healthcare capabilities in Asia Pacific. From the recently opened Clark hub in the Philippines to healthcare cold-chain capability investments, UPS is building a stronger regional network that gives customers faster, more reliable connections to markets around the world.

The transaction is expected to close in the first half of 2027, subject to customary regulatory reviews and approvals. The value and terms of the transaction are not being disclosed at this time.

Healthcare continues to be an important growth area for UPS, with revenue reaching $3 billion for the third consecutive quarter in Q3. The planned acquisition builds on that strategy adding specialized capabilities as UPS Healthcare, the world’s No. 1 provider of complex healthcare logistics, continues healthcare investments across Asia Pacific.

For more information about UPS innovations and customer-driven solutions, visit about.ups.com.

About UPS

UPS (NYSE: UPS) is one of the world’s largest companies, with 2025 revenue of $88.7 billion, and provides a broad range of integrated logistics solutions for customers in more than 200 countries and territories. Focused on its purpose statement, “Moving our world forward by delivering what matters,” the company’s approximately 460,000 employees embrace a strategy that is simply stated and powerfully executed: Customer First. People Led. Innovation Driven. UPS is committed to reducing its impact on the environment and supporting the communities we serve around the world. More information can be found at www.ups.com, about.ups.com and www.investors.ups.com.

About UPS Healthcare

UPS Healthcare delivers unparalleled healthcare logistics expertise to its customers around the world. UPS Healthcare has 21+ million square feet of cGMP and GDP-compliant healthcare distribution space globally. Services include inventory management, cold chain packaging and shipping, storage and fulfillment of pharmaceuticals, medical devices, and lab and clinical trial logistics. UPS Healthcare's global infrastructure, its UPS® Premier visibility service, its track and trace technology, and its global quality system are well-suited to meet today's complex logistics demands for the pharmaceutical, medical device, and laboratory diagnostic industries. Visit Healthcare.ups.com for more information.

About Smartways Logistics

Smartways provides time critical and complex logistics services to the healthcare ecosystem in Australia, New Zealand and the Asia Pacific region. Clients include the world’s largest companies in the medical device, pharmaceutical, life science, clinical trial and radiopharmaceutical services. With over 350 drivers, Smartways has the largest dedicated healthcare network in the region providing next flight out, same day ground, overnight transportation, reverse logistics and 3PL solutions where every service provided has an impact on a patient outcome. Visit Smartwayslfl.com for more information.

UPS Media Relations
pr@ups.com

Source: UPS

Key Terms

radiopharmaceuticals medical
Radiopharmaceuticals are medicines that carry tiny amounts of radioactive material to help doctors see or treat disease inside the body, acting like a tracer dye for imaging or a microscopic guided missile for targeted therapy. They matter to investors because their safety, regulatory approval, production complexity, short shelf life and hospital reimbursement determine how quickly they can reach patients and generate revenue, affecting a company’s sales potential and risk profile.
cold-chain technical
A cold-chain is the refrigerated logistics system that keeps temperature-sensitive products—such as vaccines, biologic drugs, and perishable foods—within a controlled temperature range from production through storage and transport to the end user. Investors care because failures in this “continuous refrigerator” can destroy product value, trigger costly recalls or regulatory penalties, and require specialized infrastructure and ongoing operating costs that affect margins and growth potential.

Keep reading